Sept 13th-16th, 2015







June 15th-18th, 2015



April 28th, 2015




March 22-26, 2015






March 9-11, 2015




Dec 3, 2014



Dec 2 and 3, 2014





Nov 19, 2014





Nov 3-5, 2014





Oct 15-17, 2014





Oct 9-12, 2014




Sept 23-25, 2014





Sept 8-13, 2014




June 21-26, 2014

May 28-30, 2014





























May 25-27, 2014





































































































































March 22,27, 2014



March 9-12, 2014



Nov 28-Dec 1, 2013





November 14-15, 2013




September 24-26, 2013



September 18, 2013


September 17, 2013



September 1-4, 2013




June 12-14, 2013


June 11-12, 2013



June 5-7, 2013


April 22-25,2013




March 22, 2013
 







 
March 10-13, 2013




December 3-4, 2012
 
 



 
November 30-
December 2, 2013
  



November 28-29, 2012 
 
 





November 26-27, 2012



 
November 20, 2012
 
  









September 24-27, 2012

 






June 17-20, 2012

51st Congress of the European Societies of Toxicology | Bridging Sciences for Safety | Porto, Portugal, Meet CapEval Pharma. It will be represented by Company’s managing director, Dr. Olivier Loget.





 BIO International Convention, Philadelphia, PA, CapEval Pharma will be represented by Company’s managing director, Dr. Olivier Loget  where he will meet new clients and put in place new projects.


AFSSI, Paris, France, Meet CapEval Pharma. It will be represented by Company’s managing director, Dr. Olivier Loget  who will present a communication. 


54th Congress of the Society Of Toxicology ,at San Diego, CA, CapEval Pharma was represented by Company’s managing director, Dr. Olivier Loget  where he met new clients and put in place new projects.




BIO Europe Spring, at Paris, CapEval Pharma was represented by Company’s managing director, Dr. Olivier Loget  where he presented a new offers for financing clients projects.



At Lille, CapEval Pharma was represented by Company’s managing director, Dr. Olivier Loget at FISE 2014, where he presented a new communication on Scientific Drug Research and Development.


At Lille, CapEval Pharma was represented by Company’s managing director, Dr. Olivier Loget at BioFIT 2014, where he presented a new communication on Scientific Drug Research and Development.

CapEval Pharma participated in the Outsourcing in Drug Development (ODD) meeting at Evreux, presented its services in Research as well as a communication on scientific preclinical research in Drug Development.



BIO Europe 2014 Conference at Francfort, Germany was a place to discuss and acquire the cutting edge knowledge on various topics including vaccines, clinical trials, regenerative medicine, bio energy, GMO, functional food, technology transfer and licensing to firmly secure the global competitiveness.
CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget.

BIO JAPAN 2014 Conference at Pacifico Yokohama: a place to discuss and acquire the cutting edge knowledge on various topics including vaccines, clinical trials, regenerative medicine, bio energy, GMO, functional food, technology transfer and licensing to firmly secure the global competitiveness where CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget.

CapEval at the13th Congress of the International Society of Ocular Toxicology at Kanazawa Bunka Hall, Japan : Capeval’s CEO, one of the Board Director, Dr. Olivier Loget chaired a session on electrophysiology. He has been elected president of the International Society of Ocular Toxicology.



CapEval Pharma at MipTec Congress 2014 at the Basel International Congress Centre, Basel, Switzerland.

CapEval Pharma was represented by its CEO, Dr. Olivier Loget
Meet CapEval Pharma at MipTec Congress 2014 at the Basel International Congress Centre, Basel, Switzerland.CapEval Pharma was represented by its CEO, Dr. Olivier Loget
Meet CapEval Pharma at MipTec Congress 2014 at the Basel International Congress Centre, Basel, Switzerland.CapEval Pharma was represented by its CEO, Dr. Olivier Loget
CapEval Pharma at Eurotox Congress 2014 at Edinburgh International Congress Centre, Scotland, UK.

CapEval Pharma was represented by its CEO, Dr. Olivier Loget

CapEval Pharma at BIO USA 2014,San Diego,CA

CapEval at BIO Korea 2014, Seoul

BIO KOREA 2014 Conference was a place to discuss and acquire the cutting edge knowledge on various topics including vaccines, clinical trials, regenerative medicine, bio energy, GMO, functional food, technology transfer and licensing to firmly secure the global competitiveness.

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget. If you are looking for expertise in discovery, preclinical/clinical development, ADMET, DDI, PK, regulatory toxicology, or ICH we can arrange an appointment with you during the meeting.

 
Period May 28(Wed) ~ 30(Fri), 2014
Venue 3~4F, Exhibition Center II, KINTEX, KOREA









Meet CapEval at Korea-Europe Biotech Business Showcase 2014, Chuncheon

Korea-Europe Biotech Business Showcase 2014 was a place to discuss opportunities for Research and Business collaborations.

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget, who presented last results in non-clinical development.









SOT 2014,Phoenix,AZ. CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget.


CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at BIO Europe Spring 2014, Turin, Italy.

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at AFVAC 2013. Nantes, France.




































































































































 



























































CapEval Pharma at SFT 2013, Paris, France

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at SFT 2013.

CapEval Pharma at MipTec 2013, Basel, Switzerland

CapEval Pharma at Bio Valley Life Sciences 2013, Basel, Switzerland

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at ODD 2013, where he made a presentation.

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at CET 2013,where he made a presentation


CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at Eurotox 2013, Interlaken, Switzerland.



CalBio 2013, San Diego
CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget.

CapEval Pharma at Biotech Tour, San Diego
CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget.

CapEval Pharma at Biotech Tour, Boston
CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget.


CapEval Pharma at Bio US 2013, Chicago
CapEval was represented by its CEO



CapEval Pharma at the Swiss Biotech Association Academy in Lausanne during the Seminar "Challenges in Drug Discovery and Development".

Dr. Manfred Schneider, CapEval Pharma's expert partner did represent the company and presented a conference on early safety tests (CYP inhibition, hERG, GSH assay etc). 




SOT 2013,San Antonio,TX. CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget.




Lille. CapEval at BioFIT 2012

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at BioFIT 2012.

 


Paris. CapEval at AFVAC

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at AFVAC.

 

 
CapEval Pharma at Informa Life Sciences 4th annual Setting Specifications, Berlin
Dr. Dawn Toronto, CapEval Pharma's expert partner represented the company and presented the following conference:

Setting specifications for API impurities and genotoxic impurities in early development: Perspective of small pharma

 

 

Frankfurt. CapEval at MRF (Minipig Research Forum)

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at Minipig Research Forum, where he chaired a session on ophthalmology.

 


Evreux. CapEval at ODD (Outsourcing in Drug Development)

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at ODD (Outsourcing in Drug Development).

 









Basel. CapEval at Mip Tec

 

CapEval Pharma was represented by Company’s CEO, Dr. Olivier Loget at Mip Tec. for developping expertise in discovery, preclinical/clinical development, ADMET, DDI, PK, regulatory toxicology, CMC,regulatory compliance, ICH, QA.

 

 

 

CapEval Pharma at Eurotox 2012


CapEval Pharma participated to the Eurotox 2012 international meeting at Stockholm and presented its global services for Non-Clinical Development
 
May 23-24, 2012
 
CapEval at the the Oncology B4B-Connection at Paris
 
  CapEval participated in the Oncology B4B-Connection at Paris and presented its services as well as a communication on preclinical development in oncology
 May 14, 2012  CapEval moved to new head quarters
   
CapEval moved from its former head quarters at Cessy to new facilities in Archamps Technopole (Le Forum 2 – 218 Avenue Marie Curie F-74160 Archamps), consisting of new offices and access to new in vitro and in vivo laboratories
 May 4, 2012
  CapEval Pharma starts a collaboration with OriBase Pharma
   
A non-clinical development partnership was signed between OriBase represented by its CEO, Dr. Aziz Yasri and CapEval represented by its CEO Dr. Olivier Loget. This partnership will allow a successful development of OriBase Pharma very promising molecules in the field of oncology.
 May 1, 2012 CapEval Pharma starts a collaboration with Splicos
  
 

 CapEval Pharma, a preclinical development consulting laboratory, represented by its CEO Dr. Olivier Loget, and SPLICOS, an innovative therapeutic company represented by its CEO and CSO, Dr. Didier Scherrer have strengthened their collaboration with a non-clinical development contract.
Under the terms of the contract, the two companies have entered into a consulting program on the development of preclinical stage drug candidates.
CapEval Pharma is a company offering a wide range of preclinical services providing development, registration as well as training services in different fields including preclinical development.
SPLICOS SAS is a cutting edge company entirely focused on R&D in the field of RNA alternative splicing. SPLICOS is developing a novel class of small molecules in the field of HIV-AIDS and oncology.
 April 26, 2012
  CapEval Pharma at the French Veterinary Academy
   
CapEval presented a comparison of non-clinical development of small molecules and monoclonal antibodies at the French Veterinary Academy.